Advertisement
New Zealand markets close in 2 hours 19 minutes
  • NZX 50

    12,144.94
    +9.97 (+0.08%)
     
  • NZD/USD

    0.6098
    -0.0023 (-0.37%)
     
  • NZD/EUR

    0.5597
    -0.0009 (-0.15%)
     
  • ALL ORDS

    8,272.30
    +66.20 (+0.81%)
     
  • ASX 200

    8,028.20
    +68.90 (+0.87%)
     
  • OIL

    82.33
    +0.12 (+0.15%)
     
  • GOLD

    2,415.20
    -5.50 (-0.23%)
     
  • NASDAQ

    20,331.49
    +120.09 (+0.59%)
     
  • FTSE

    8,252.91
    +29.57 (+0.36%)
     
  • Dow Jones

    40,000.90
    +247.10 (+0.62%)
     
  • DAX

    18,748.18
    +213.58 (+1.15%)
     
  • Hang Seng

    18,128.42
    -164.96 (-0.90%)
     
  • NIKKEI 225

    41,190.68
    -1,033.32 (-2.45%)
     
  • NZD/JPY

    96.2720
    -0.3350 (-0.35%)
     

The Zacks Analyst Blog Highlights AbbVie, Intel, Qualcomm, Regeneron and CME Group

For Immediate Release

Chicago, IL – May 25, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: AbbVie Inc. ABBV, Intel Corp. INTC, Qualcomm Inc. QCOM, Regeneron Pharmaceuticals, Inc. REGN and CME Group Inc. CME.

Here are highlights from Wednesday’s Analyst Blog:

Top Research Reports for AbbVie, Intel and Qualcomm

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc., Intel Corp. and Qualcomm Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Shares of AbbVie have underperformed the Zacks Large Cap Pharmaceuticals industry over the past year (-2.6% vs. +9.8%). There are concerns about long-term sales growth as Humira generics have entered the U.S. market. Increasing competition from newer therapies is hurting Imbruvica’s sales. Slowing consumer demand due to economic pressure is hurting the aesthetics franchise’s sales.

Nonetheless, though revenues are expected to decline in 2023, AbbVie expects to return to robust sales growth in 2025. AbbVie has several new drugs in its portfolio with the potential to drive the top line to make up for lost Humira revenues.

Skyrizi and Rinvoq have established outstanding launch trajectories bolstered by approval in new indications. The company has several early/mid-stage candidates that have blockbuster potential.

(You can read the full research report on AbbVie here >>>)

Intel’s shares have gained +2.2% over the past six months against the Zacks Semiconductor - General industry’s gain of +49.3%. The company is witnessing healthy momentum in its data center business with integrated affordable solutions. Heavy investment in research and development to drive technological innovation and concerted focus on increasing market diversification are tailwinds.

Intel is increasingly focusing on a diversified product range targeting different segments of the market. Healthy traction from Mobileye’s technologies related to in-car networking, sensor-chips, cloud software, machine learning and data management are positives.

However, an uncertain macroeconomic environment, PC inventory correction, contraction in the server market and high debt burden are affecting its margins. A highly competitive market and manufacturing delays are hurting Intel’s profitability. Signs of market saturation, foreign exchange headwinds and geopolitical instability are worrisome.

(You can read the full research report on Intel here >>>)

Shares of Qualcomm have underperformed the Zacks Wireless Equipment industry over the past six months (-15.1% vs. +12.9%). The company’s global presence exposes it to risk of trade disputes and geopolitical tensions. High dependence on the smartphone industry is a headwind as weak consumer demand trends can significantly affect margins. Macroeconomic uncertainty and competition from other low-cost chip manufacturers remain other concerns.

Nevertheless, Qualcomm is well-positioned to benefit from solid 5G traction with greater visibility and a diversified revenue stream. The EDGE networking business is witnessing steady progress as it focuses on transitioning from a wireless communications firm for the mobile industry to a connected processor company for the intelligent edge.

It is likely to help users experience a seamless transition to super-fast 5G networks, delivering low-power resilient multi-gigabit connectivity with unprecedented range and best-in-class security.

(You can read the full research report on QUALCOMM here >>>)

Other noteworthy reports we are featuring today include Regeneron Pharmaceuticals, Inc. and CME Group Inc.

Why Haven’t You Looked at Zacks' Top Stocks?

Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.

ADVERTISEMENT

See Stocks Free >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

https://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Intel Corporation (INTC) : Free Stock Analysis Report

Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report

QUALCOMM Incorporated (QCOM) : Free Stock Analysis Report

CME Group Inc. (CME) : Free Stock Analysis Report

AbbVie Inc. (ABBV) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research